1. Trigger day is a question of follicular development measured in days; the trigger-to-retrieval interval is checked in hours from actual administration.
2. In selected populations, a one-day delay yields roughly one additional oocyte on average, without an established live-birth benefit. A two-day delay reduced ongoing pregnancy in a fresh-transfer randomized trial.
3. A commonly used retrieval interval is 34–38 hours. The centre determines the exact schedule with the trigger method and individual circumstances.
Abstract
During the final days of stimulation, waiting another day involves the entire follicular cohort, the leading follicles and the transfer plan. Smaller follicles may not yet have sufficient developmental capacity when the trigger is given early; during a delay, the leading follicles and hormonal environment also change. After triggering, final maturation has a separate window measured in hours. This article reviews follicle size and mature-oocyte yield, studies of 24- and 48-hour delays, uneven follicular cohorts and timing associations with different triggers. It retains a cycle-review table and questions to discuss with the treating doctor.[1,2,3,4]
Keywords: trigger timing; follicle diameter; delayed trigger; premature progesterone elevation; retrieval interval; mature oocytes.
01 Trigger day and the retrieval interval
“Early” or “late” triggering can refer to two things. Trigger day concerns follicle size and the day of stimulation on which medication is administered. A day's difference may correspond to approximately 1.5–2 mm of average follicular growth. The trigger-to-retrieval interval concerns the hours between medication administration and the start of retrieval, commonly 34–38 hours.[2]
Trigger day affects the developmental stage of the cohort at administration; the interval affects final maturation and the possibility of ovulation before retrieval. Review follicle size, actual administration and retrieval start separately. Extending the interval may not compensate for insufficient follicular development. Changing the next cycle's trigger day also requires checking whether medication was administered as instructed.
Figure 1 · Two dimensions of “early” and “late”
Based on the follicular cohort and clinical context.
Illustrative stimulation days: 8 → 9 → 10 → 11 → 12. Day 10 is the schematic planned trigger, with one day earlier or later on either side.
Count from actual trigger administration (0 h).
Illustrative scale: 0 → 12 → 24 → 34–38 → 42 h. The commonly used retrieval interval is 34–38 h.
The day sequence is illustrative, not a prescribed stimulation length. Review these dimensions separately; the centre determines the schedule.
02 Guidance and individual assessment
The 2025 update of the ESHRE ovarian stimulation guideline describes triggering final maturation most often when several leading follicles are between 16 and 22 mm. This is a good practice point, rather than a rigid cutoff established by randomized trials. The guideline advises against deciding timing from estradiol alone or the estradiol-to-follicle ratio alone.[1]
More specific criteria, such as at least three follicles measuring 17 mm or two measuring 18 mm, are operational criteria used by individual centres and studies. They differ. Many delay trials begin once such a criterion has been reached and compare triggering then with triggering later.[8]
Assessment also includes the entire size distribution, hormone findings, stimulation duration, ovarian hyperstimulation syndrome (OHSS) risk, fresh-transfer plans and previous cycle experience. A leading follicle of 18 mm may therefore lead to different decisions in a synchronized cohort and a widely dispersed one.
Monitoring and blood hormones
ESHRE conditionally advises against routinely adding estradiol, or a panel of estradiol, progesterone and LH, to ultrasound monitoring. Its trigger-day recommendations address distinct circumstances: progesterone measurement is probably recommended when fresh transfer is planned, while deferring transfer should also consider oocyte and embryo numbers and embryo quality. In hCG-triggered cycles intended for fresh transfer, routine trigger-day estradiol measurement and trigger-day LH measurement are not recommended. In GnRH-agonist-triggered freeze-all cycles, measurement of all three hormones on that day is not recommended. The treating team decides whether a specific clinical concern warrants additional tests. These recommendations do not mean that ultrasound always determines trigger day or that every discussion of a delay requires progesterone and LH testing.[1]
03 Earlier triggering and smaller follicles
The trigger allows the oocyte to resume meiosis: from the germinal vesicle (GV) stage through metaphase I (MI), extrusion of the first polar body and metaphase II (MII), the stage ready for fertilization. Oocytes in smaller follicles may not yet have the capacity to complete this process and are more likely to remain at GV or MI after retrieval.
Which follicle sizes contribute most mature oocytes?
Abbara and colleagues analyzed 499 cycles in 2018. Follicles measuring 12–19 mm on trigger day contributed most to retrieved and mature oocytes. Comparing the highest with the lowest third of patients by the proportion of follicles in this range, mature-oocyte yield was higher by an average of 4.7 with hCG and 4.9 with a GnRH agonist trigger.[3]
Hanassab and colleagues' 2025 multicentre study analyzed 19,082 patients undergoing their first treatment at 11 European centres using explainable machine learning. Maturity analysis used 14,140 ICSI cycles with maturity grading. Follicles at 13–18 mm contributed most overall. For patients older than 35, the range extended to 11–20 mm, particularly 15–18 mm. In hCG-triggered protocol subgroups, ranges were 12–19 mm for antagonist cycles and 14–20 mm for long agonist protocols. Prospective validation remains necessary.[4]
Figure 2 · Trigger-day size and mature-oocyte contribution
Abbara 2018: 12–19 mm contributed most to oocyte and MII yield.
Hanassab 2025: 13–18 mm overall, especially 15–18 mm.
Older than 35: 11–20 mm.
Antagonist: 12–19 mm; long protocol: 14–20 mm.
Small-to-large size scale in the source: 6–28 mm. It is illustrative, not a diagnostic maturity or overmaturity scale. These study ranges are not individual cutoffs. Follicles may grow another 2–3 mm before retrieval. Sources [3,4].
Measurement day matters. Those studies used trigger-day sizes; others measure follicles during aspiration on retrieval day. Follicles may grow another 2–3 mm after triggering. Shapiro and colleagues' 2022 study followed 4,539 follicles across 157 retrievals. High-quality blastocyst yield per follicle rose from 2.2% at ≤9.5 mm on retrieval day to 18.9% at 19–21.5 mm, remaining around 16–18% at larger sizes. Follicles ≤12.5 mm performed below the overall average. Trigger-day and retrieval-day measurements cannot be interchanged.[5]
Ultrasound also has measurement uncertainty. Follicles are not perfectly circular, and diameters are usually averaged across two or three axes. Operators and equipment may differ by millimetres. An 18 mm and a 19 mm reading do not represent sharply distinct biological states. The whole distribution is often more informative than one reading; ranges such as 12–19 mm are population associations, not requirements for every oocyte to mature.[3,4]
Randomized evidence on an earlier trigger
Mochtar and colleagues' 2011 trial at four Dutch centres compared administering hCG when the leading follicle reached 18 or 22 mm after downregulation in a long protocol. These were follicle sizes at triggering, not immediate retrieval at those diameters. Ongoing pregnancy was 38% (37/97) in the 22 mm group and 24% (22/93) in the 18 mm group: relative risk 1.6, 95% confidence interval 1.03–2.5.[6]
The trial planned 400 participants but completed 190. After adjustment for age, fertilization method and centre, the difference was no longer statistically significant (OR 2.0, 95% CI 0.96–4.2). It used long protocols and fresh transfers. A later trigger may have benefited that population, but the study establishes neither a universal 22 mm rule nor direct applicability to antagonist or freeze-all cycles.
An earlier trigger can have a different rationale
Wu, Gleicher and colleagues' 2018 single-centre retrospective study in women with low ovarian reserve compared 56 women aged ≥43 at leading-follicle sizes of 13.5–15.5, 16–18 and 18.5–20.5 mm at trigger. Clinical pregnancy was 16.7% in the 16–18 mm group, versus 5.9% and 6.7% in the other two groups. In another 37 younger women, a subgroup described as having “premature ovarian aging,” conventional timing yielded 7.7% versus 41.7% with earlier timing. That study term is not equivalent to a diagnosis of premature ovarian insufficiency. The authors proposed premature luteinization as an explanation; the observational design cannot establish that waiting itself damaged oocyte quality.[7]
04 Delaying the trigger: yield and transfer outcomes
A delay may allow smaller follicles to continue developing, while the leading follicles and hormones also change. Studies need to distinguish total oocytes, mature oocytes and later transfer outcomes.
A 24-hour delay
Xie and colleagues' 2024 meta-analysis included six studies and 1,360 normal responders using antagonist protocols. Delayed triggering yielded 1.2 additional oocytes on average, or 1.31 in the 24-hour subgroup. Differences in embryo count, clinical pregnancy and live birth were not statistically significant; stimulation duration and total gonadotropin dose increased. Failure to detect a significant difference does not establish equivalence.[8] Chen and colleagues' 2014 meta-analysis reported a similar direction: more oocytes, without significant differences in ongoing pregnancy, miscarriage or live birth. The authors discussed the scheduling convenience of a one-day delay, such as avoiding weekend retrieval.[9]
Vandekerckhove and colleagues' 2014 randomized trial stratified patients by progesterone after at least three follicles reached 18 mm. In the subgroup with progesterone ≤1 ng/ml and 30–50% of follicles larger than 10 mm measuring at least 18 mm, mean MII yield was 10.29 after a 24-hour delay versus 7.64 with triggering as scheduled. In the >1 ng/ml stratum, yield was 12.03 with scheduled triggering versus 11.81 after delay, without an increase. Pregnancy differences were not significant, but the trial was not powered for pregnancy outcomes. The 1 ng/ml value was a study stratification criterion, not a universal threshold for deciding whether to wait.[10]
A 48-hour delay
Kolibianakis and colleagues' 2004 randomized trial included 413 patients using antagonists and compared triggering once at least three follicles reached 17 mm with waiting two more days. Fertilization, embryo numbers and quality did not differ significantly. Ongoing pregnancy was 25.0% after delay versus 35.6% with immediate triggering.[11] The 48-hour subgroup in Xie's meta-analysis likewise showed no significant oocyte-yield increase.[8]
The trial involved fresh transfer. Endometrial–embryo asynchrony was a possible explanation discussed by the authors, not a mechanism directly demonstrated by the trial. Freeze-all changes the immediate transfer environment, but it does not establish that delaying has no follicular cost or effect on cumulative live birth.
Potential costs
Venetis and colleagues' 2013 meta-analysis covered more than 60,000 cycles. In fresh cycles, analyses using progesterone thresholds starting at 0.8 ng/ml associated elevation with lower pregnancy probability; the OR in the 1.5–1.75 ng/ml threshold group was 0.64. Different study thresholds are not a single boundary for individual risk. The same adverse association was not observed in frozen transfers or donor-oocyte recipient cycles.[12] Hanassab also associated a larger proportion of follicles above 18 mm with progesterone elevation and lower fresh-transfer live birth.[4]
During a delay, clinicians consider growth of the leading follicles, hormone changes, premature luteinization or ovulation and prior retrieval difficulties (related findings are discussed in Vol.124). OHSS risk requires the overall response, hormones, trigger method and transfer strategy; it cannot be inferred from an extra day's wait alone. Longer stimulation also adds medication, cost and injection burden.
Why additional oocytes may not establish a live-birth benefit
The developmental potential of smaller follicles and attrition through fertilization, cleavage and blastocyst formation may help explain differences between yield and live birth. These mechanisms were not directly established in the delay trials. Many studies involved fresh or first transfers and limited samples. Evidence for cumulative live birth in freeze-all cycles remains insufficient. Selected populations may obtain more oocytes after a one-day delay, but a live-birth benefit has not been established.[5,8,9,10]
| Study | Design and population | Comparison | Main finding | Interpretation |
|---|---|---|---|---|
| Kolibianakis 2004 [11] | Randomized; 413; antagonist; fresh transfer | Trigger at criterion vs 2-day delay | Ongoing pregnancy 35.6% vs 25.0%; fertilization and embryo quality not significantly different | Applies to this fresh-transfer trial; endometrial explanation is hypothetical |
| Mochtar 2011 [6] | Randomized; 190; long protocol; fresh transfer | Trigger at leading follicle 18 vs 22 mm | Ongoing pregnancy 24% vs 38%; nonsignificant after adjustment | Under-recruited; no universal diameter established |
| Chen 2014 [9] | Meta-analysis; agonist and antagonist protocols | Scheduled vs 24/48-hour delay | More oocytes; ongoing pregnancy and live birth not significantly different | Scheduling convenience discussed; equivalence not established |
| Vandekerckhove 2014 [10] | Randomized; progesterone strata | Scheduled vs 24-hour delay | Selected ≤1 ng/ml subgroup: MII 7.64 vs 10.29; no increase at >1 | See subgroup conditions above; not powered for pregnancy |
| Xie 2024 [8] | Meta-analysis; 6 studies; 1,360; antagonist | Scheduled vs 24/48-hour delay | Mean increase 1.2 oocytes; embryo, pregnancy and live-birth differences nonsignificant | No yield benefit detected in the 48-hour subgroup |
Table 1. Main studies of earlier and delayed triggering, ordered by publication year.
Figure 3 · Earlier and later triggering: potential tradeoffs
Possible gains: less continued growth of leading follicles; less exposure to progesterone rise; fewer stimulation days and injections.
Possible costs: less development of smaller follicles, fewer retrieved oocytes or more immature oocytes.
Possible gains in studied populations: roughly one more total oocyte on average; approximately two more MII oocytes in a selected low-progesterone subgroup.
Limits and possible costs: no established live-birth benefit; lower ongoing pregnancy after a two-day delay in a fresh-transfer trial; changing hormones and leading follicles.
Potential mechanisms and trial findings should not be conflated. Total-oocyte and MII increases come from different populations. Nonsignificant live-birth differences do not establish equivalence. Sources [6,7,8,9,10,11,12].
05 An uneven follicular cohort
A difficult situation is a cohort with leading follicles at 18–20 mm and others at 12–15 mm. Earlier triggering may limit the contribution of smaller follicles; waiting also changes the leading ones. One diameter cannot resolve the tradeoff, which requires current clinical information.
Consider two hypothetical cycles to understand the variables, rather than decide treatment. Cycle A has three leading follicles at 18–19 mm, six at 14–16 mm and progesterone 0.6 ng/ml. Cycle B has the same leading sizes, but other follicles at 10–12 mm and progesterone 1.4 ng/ml. The smaller-follicle distribution and hormones differ, so potential benefits of waiting may differ. Vandekerckhove's trial supports an increase in MII yield in a selected low-progesterone subgroup. These numbers cannot determine whether either hypothetical cycle meets all trial conditions or how it will change tomorrow.[10]
Discussion can review leading-follicle growth, the proportion at intermediate sizes such as 14–16 mm, available progesterone or LH findings and the need for testing, suppression protocol, ovarian reserve, prior premature luteinization, OHSS risk and fresh or frozen transfer plans. Neither 22 mm, 1 ng/ml nor a follicle proportion is a validated standalone rule for waiting. The treating team assesses the whole cycle.
Figure 4 · Variables to review in an uneven cohort
Source schematic starts with several leading follicles at 16–18 mm.
Review progesterone or LH findings when clinically indicated, leading-follicle growth, and the proportion of 14–16 mm follicles.
Review the suppression regimen, reserve, previous LH surge or luteinization, OHSS risk and fresh-transfer plan.
The doctor decides whether triggering now or waiting 24 h with appropriate reassessment is justified.
The source uses 22 mm and yes/no branches as an explanation of variables. Those branches and values are not a validated clinical algorithm. Hormone tests and repeat monitoring are individualized; no branch prescribes timing. Sources [1,10].
Asynchrony also merits discussion before the next cycle. ESHRE conditionally advises against routine gonadotropin dose increases or decreases during stimulation; this does not establish that every adjustment is ineffective. The team can use previous response to discuss the next starting dose, protocol and monitoring, without promising that a change will synchronize the cohort.[1]
06 From trigger to retrieval: timing in hours
The trigger initiates meiotic resumption, cumulus expansion and follicular-wall changes. Retrieval balances final maturation against ovulation before the procedure, with variation by individual and trigger method. ESHRE's retrieval recommendations describe approximately 36 hours as recommended by most authors, with a commonly used range of 34–38 hours. Patients should not choose their own time within this range.[2]
Shorter and longer intervals
Wang and colleagues' 2011 meta-analysis of five randomized trials and 895 patients found a higher mature-oocyte proportion with longer intervals, without significant differences in fertilization, implantation or pregnancy.[13] Gan and colleagues' 2023 update included 12 studies and compared intervals below and above 36 hours. Maturation rates were similar, clinical pregnancy was higher in the longer-interval group, and the live-birth difference was not statistically significant. Definitions and study quality varied; further adequately designed randomized trials were recommended.[14]
The early ovulation observations cited by Gan were inconsistent: one study reported mean first follicular rupture around 38.3 hours, another observed no ovulation through 41 hours, and earlier ovulation also occurred in individual cases. A 39-hour boundary came from some early observations. Neither 38 nor 39 hours separates safe from unsafe timing for everyone. This evidence does not support independently delaying medication or retrieval.[14]
Check whether an interval ends at retrieval start or completion. Retrieval of multiple follicles may take 30–40 minutes, producing different intervals for the first and last oocytes. Record actual administration, procedure start and completion, and ask the centre to explain its scheduling. Procedure duration does not establish a personal trigger time.
Associations vary by trigger method
Enatsu and colleagues' 2025 single-centre retrospective study analyzed 59,206 cycles over 14 years using <36.5 and ≥36.5 hours. Distinguish Table 2's total oocytes from MII oocytes: with a GnRH agonist, longer versus shorter intervals yielded 7.2 versus 4.3 total oocytes and 5.8 versus 3.5 MII oocytes; with hCG, the corresponding numbers were 4.0 versus 6.9 and 3.2 versus 5.5. The article's narrative labels the first total-oocyte figures as MII, conflicting with the table; this page follows the table labels. Maturation proportions did not differ significantly for either trigger, and association strength varied by age. These are observational associations, not individual optimal hours.[15]
Figure 5 · From trigger to retrieval
Approximately 36 h; commonly 34–38 h.
Too little time may limit maturation; excessive delay may permit ovulation. Neither 38 nor 39 h is a universal rupture boundary.
At ≥36.5 vs <36.5 h: total oocytes 4.0 vs 6.9; MII oocytes 3.2 vs 5.5.
Maturation proportions did not differ significantly.
At ≥36.5 vs <36.5 h: total oocytes 7.2 vs 4.3; MII oocytes 5.8 vs 3.5.
Maturation proportions did not differ significantly.
Source timeline: 24–42 h. The approximately 39 h mark comes from selected early observations, not a universal safe/unsafe cutoff. Enatsu table labels separate total and MII yield; observational groups do not prescribe intervals. Sources [2,13,14,15].
If medication timing is wrong
Practical errors include misremembered injection times, early or late administration and confusion between local and home-country time zones. A two- or three-hour time-zone difference can move the interval toward the edge of the planned window.
- Write the trigger time in the retrieval centre's local time; use the same time zone for the prescription, alarm and procedure schedule.
- Record actual administration and tell the doctor before retrieval. ESHRE recommends confirming the time.[2]
- Contact the centre immediately if administration deviates from instructions or delivery is uncertain; do not wait for an error to exceed one hour. The doctor determines whether blood or urine hCG testing or rescheduling is appropriate after an hCG trigger. Do not repeat the trigger or change other medication independently.[2]
07 Reviewing timing after retrieval
Retrieval and embryology findings can guide questions for a later cycle. The following are review clues, not diagnoses. Maturity also depends on age, ovarian response, laboratory handling and intrinsic oocyte factors.
| Retrieval finding | Possible review direction | Original records |
|---|---|---|
| Immature oocytes mainly from smaller follicles | Trigger day and development of the cohort | Size distribution, stimulation days, starting dose |
| Suitable follicle sizes but many immature oocytes | Interval, medication delivery, trigger response and other causes | Actual administration and time zone, retrieval start, medication and dose |
| Normal yield and maturity with elevated trigger-day progesterone | Endometrial conditions for fresh transfer | Progesterone, transfer plan; discuss whether to freeze embryos |
| Poor yield from large follicles with elevated progesterone | Timing, luteinization and retrieval-process factors | Progesterone and LH, leading sizes; see Vol.124 |
| Collapsed follicles or pelvic fluid | Possible early ovulation, with other causes also considered | Pre-trigger hormones, actual interval, pre-retrieval ultrasound |
Table 2. Timing-review clues after retrieval. Check complete records; a single finding cannot establish a diagnosis.
The first two rows are easily confused. Immature oocytes concentrated in smaller follicles raise questions about trigger day; immature oocytes despite suitable sizes also require medication timing, interval and trigger response to be reviewed. Vol.119 discusses trigger-method selection.
08 Five questions for the doctor
The doctor determines trigger timing. Understanding the following points can help patients follow the schedule and later reconstruct the cycle.
- What follicle criterion is planned: how many follicles at which diameter?
- How large are the leading and smaller follicles, and how might the leaders change over another day?
- Does this cycle need progesterone or LH testing? How would existing results affect triggering or transfer?
- What interval is planned, and is the trigger hCG, an agonist or a combination?
- If the cohort is uneven, what changes can be considered before the next cycle begins?
Three practical actions
- Follow the prescribed trigger time and record actual administration; use the retrieval centre's local time across time zones.
- Do not change stimulation medication or start anti-inflammatory painkillers independently; discuss medication needs with the doctor.
- Keep original ultrasound, blood-test and medication records for cycle review or a change of centre.
Conclusion
Scope and limitations
This article reviews population evidence, not identifiable patients, and does not prescribe medication or scheduling. Randomized trials were limited, some used long protocols or fresh transfers, meta-analysis definitions varied, and retrospective findings establish associations. Trigger day, medication and retrieval time are clinical decisions. Information diagrams are editorial schematics; the cover and supplementary artworks are AI-generated concepts, not patient medical images. Evidence and translation review for this web page was completed on 10 October 2026; it does not constitute individual clinical approval.
Review timing using complete cycle records
FS can help organize ultrasound, hormone, medication and laboratory records. The treating team determines the trigger day, medication and retrieval schedule.
References and original guidance
Numbers correspond to the text. The source manuscript searched evidence through 9 October 2026; key claims and guidance were reviewed for this page on 10 October. Study conditions and corrected outcome labels are explained in the article.
- ESHRE Guideline Group on Ovarian Stimulation. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025. Hum Reprod. 2026;41(4):498–514.
- ESHRE Working Group on Ultrasound in ART. Recommendations for good practice in ultrasound: oocyte pick up. Hum Reprod Open. 2019;hoz025.
- Abbara A, et al. Follicle size on day of trigger most likely to yield a mature oocyte. Front Endocrinol. 2018;9:193.
- Hanassab S, et al. Explainable artificial intelligence to identify follicles that optimize clinical outcomes during assisted conception. Nat Commun. 2025.
- Shapiro BS, et al. The effect of ovarian follicle size on oocyte and embryology outcomes. Fertil Steril. 2022. PMID 35367061.
- Mochtar MH, et al. Timing oocyte collection in GnRH agonists down-regulated IVF and ICSI cycles: a randomized clinical trial. Hum Reprod. 2011. PMID 21362684.
- Wu YG, Barad DH, Kushnir VA, et al. With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization. J Ovarian Res. 2018;11:23.
- Xie Q, et al. Meta-analysis of trigger timing in normal responders undergoing GnRH antagonist ovarian hyperstimulation protocol. J Ovarian Res. 2024;17:56.
- Chen Y, et al. Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis. Gynecol Endocrinol. 2014;30(6):431–437.
- Vandekerckhove F, et al. Delaying the oocyte maturation trigger by one day leads to a higher metaphase II oocyte yield in IVF/ICSI: a randomised controlled trial. Reprod Biol Endocrinol. 2014;12:31.
- Kolibianakis EM, et al. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant FSH and GnRH antagonists. Fertil Steril. 2004. PMID 15236997.
- Venetis CA, et al. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013. PMID 23827986.
- Wang W, et al. The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis. J Assist Reprod Genet. 2011. PMID 21792666.
- Gan R, et al. Time interval between hCG administration and oocyte retrieval and ART outcomes: an updated systematic review and meta-analysis. Reprod Biol Endocrinol. 2023;21:61.
- Enatsu N, et al. Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use. F&S Rep. 2025. PMID 41473569.
For public medical education only; not individual medical advice.